DRTG(SH:600329) Zhi Tong Cai Jing·2025-11-25 07:57Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Loxoprofen Sodium Gel Patch, which is intended for the treatment of inflammation and pain associated with osteoarthritis, muscle pain, and post-injury swelling and pain [1] Group 1: Product Development - The approved product will serve as a starting point for the company to establish a modern traditional Chinese medicine patch technology platform that integrates research, production, and quality control [1] - The company aims to create a product matrix that covers chemical drugs, traditional Chinese medicine, and health patches, providing more medication options and improving patient experience [1] Group 2: Regulatory Approval - The Loxoprofen Sodium Gel Patch has been registered as a Class 4 chemical drug, and its approval is considered equivalent to passing the consistency evaluation [1] - The approval indicates that the product meets the relevant requirements for drug registration and is not expected to have a significant impact on the company's recent performance [1]